All In Biotech

Drug Trial Radar · NCT04590404

Metabolism Informed Smoking Treatment: The MIST RCT

Metabolism Informed Smoking Treatment in Medicaid and Medicare Patients: The MIST RCT

Last checked: Nov 19, 2026Latest source record: Dec 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 606 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

606

Actual

Start

Nov 17, 2020

Primary completion

May 20, 2024

Study completion Nov 22, 2024

Sponsor

Lead sponsor
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI); National Institutes of Health (NIH)
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 3 randomized controlled trial will test Metabolism-Informed Smoking Treatment (MIST), a precision approach to smoking treatment that biologically tailors medication selection to nicotine metabolism.

Conditions

  • Smoking

Interventions

  • Post-discharge automated phone calls (IVR) with option to connect with a tobacco coach.Behavioral

    Automated calls to assess smoking status, medication use, and additional support for quit attempt.

  • Nicotine Replacement TherapyDrug

    FDA-approved forms of nicotine replacement therapy for smoking cessation.

  • VareniclineDrug

    FDA-approved smoking cessation medication.

  • Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)Other

    Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy. NMR is a blood test to measure how fast the body breaks down nicotine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biochemically-validated Past 7-day Point Prevalence Tobacco AbstinenceTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University Medical Center ViTAL, Vanderbilt Center for Tobacco, Addiction, and Lifestyle General Internal Medicine and Public Health 2525 West End Ave, Suite 450

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.